AstraZeneca inks a $538 million sales rights contract with Luye Pharma
Date: 2018-05-08   Author: Saif Ali Bepari  Category: #news

The Anglo-Swedish pharmaceutical major AstraZeneca has apparently announced to have sold the rights for Seroquel and Seroquel XR treatments, to Luye Pharma for an approximate $538 million. As per reports, the deal is in line with AstraZeneca’s strategy that aims to focus on its three chief therapy areas which include Renal & Metabolism and Respiratory, Cardiovascular, and Oncology.

Trusted sources claim that once the transaction is concluded, it would provide a total sum of USD 260 million to AstraZeneca and the outstanding amount would be paid at a later date.

For the record, Seroquel and Seroquel XR are atypical anti-psychotic medicines and are predominantly utilized to treat bipolar disease and schizophrenia. The latest agreement allows the Hong Kong headquartered Luye Pharma Group to sell these drugs in numerous international markets such as China, the UK, South Africa, Malaysia, Argentina, Thailand, South Korea, Mexico, Saudi Arabia, Australia, and Brazil.

Speaking on the development, AstraZeneca’s Executive Vice President, Mark Mallon was quoted stating that the latest agreement is part of the firm’s prospective plans to concentrate on three major therapy areas. He further stated that the deal would enhance the value of the legacy medicines like Seroquel.

As per reliable reports, AstraZeneca’s Seroquel has lost its compound patent protection globally. Moreover, the patents of Seroquel XR formulation have also expired in numerous markets across the world. In the financial year of 2017, Seroquel XR generated an annual sales revenue of about $63 million in the markets covered by these agreements while Seroquel made $85 million.

As has been reported, AstraZeneca had partnered the rights to Seroquel XR and Seroquel in Venezuela and Japan under previously signed contracts.

Subject to regulatory clearances and customary closing conditions, the latest deal is anticipated to be concluded by the end of second half of this year, cite sources.



About Author


Saif Ali Bepari

Saif Ali Bepari

Saif currently works as a content writer at Algosonline. A Computer Science graduate who has a zest for writing over coding, commenced his journey in the writing industry as a freelancer. Having had a prior freelance experience, he has tinkered with creative writing, ...

Read More

More from Saif


Post Recommendents

Walmart and JD.com provide $500m funding to Chinese logistics company
Author: Pankaj Singh

Dada-JD Daojia, a Chinese online grocery delivery service has reportedly raised USD 500 million in a recent funding round led by U.S. retail giant Walmart and Chinese e-commerce company JD.com. Sources inform that the ...


3D Systems & GF Machining team up to develop factory of the future
Author: Saif Ali Bepari

South Carolina based 3D Systems has reportedly announced a partnership with GF Machining Solutions with the aim of redefining how manufacturers think about their manufacturing setup. Sources cite that the new manufactu...


ITV invests USD 1 billion with Hollywood giants to launch NewT
Author: Ojaswita Kutepatil

ITV, a commercial television channel of the United Kingdom has reportedly collaborated with major Hollywood studios including 21st Century Fox, Disney, and others. Two huge Wall Street banks and the billionaire Walton ...